Hims, Super Bowl and Food and Drug Administration
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers hit the bulls-eye with its Super Bowl ad—it sparked a lot of attention from consumers to check out its brand and ...
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback